Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Approximate equivalent rosuvastatin doses for temporary statin interchange programs.

Michael G Kendrach1, Maisha Kelly-Freeman

  • 1Department of Pharmacy Practice; Samford University Global Drug Information Service, McWhorter School of Pharmacy, Samford University, Birmingham, AL 35229-7027, USA. mgkrendra@samford.edu

The Annals of Pharmacotherapy
|June 10, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Use of a Video Module to Improve Faculty Understanding of the Pharmacists' Patient Care Process.

Innovations in pharmacy·2021
Same author

Effect of an Individualized Post-Examination Instructor Remediation on Pharmacy Student Performance in a Biochemistry Course.

American journal of pharmaceutical education·2018
Same author

Google Scholar versus PubMed in locating primary literature to answer drug-related questions.

The Annals of pharmacotherapy·2009
Same author

Preparing students for community pharmacy practice during a drug information advanced practice experience.

American journal of pharmaceutical education·2007
Same author

Student perceptions of online lectures and WebCT in an introductory drug information course.

American journal of pharmaceutical education·2007
Same author

Accuracy of abstracts for original research articles in pharmacy journals.

The Annals of pharmacotherapy·2004
Same journal

Stability of Ceftazidime-Avibactam: Changes in Regulatory Information and Implications for Preparation.

The Annals of pharmacotherapy·2026
Same journal

Impact of Early Dose Adjustment of Piperacillin/Tazobactam on Mortality in Critically Ill Patients With Acute Kidney Injury: A Retrospective Multicenter Cohort Study.

The Annals of pharmacotherapy·2026
Same journal

Severe Phototoxic Skin Reaction Associated With Vandetanib: Implications for Pharmaceutical Care.

The Annals of pharmacotherapy·2026
Same journal

Efficacy and Safety of Oral PCSK9 Inhibitors in Adults With Hypercholesterolemia: An Updated Systematic Review and Meta-Analysis of RCTs.

The Annals of pharmacotherapy·2026
Same journal

RSVpreF: A Vaccine for the Respiratory Syncytial Virus.

The Annals of pharmacotherapy·2026
Same journal

Severe Acute Hepatitis Induced by Combined Rosuvastatin and Ticagrelor Therapy Post-PCI: The Challenges of Multi-Drug DILI Diagnosis.

The Annals of pharmacotherapy·2026
See all related articles

Rosuvastatin is not equivalent to other statins on a milligram-to-milligram basis. This cholesterol-lowering drug is significantly more potent than atorvastatin, simvastatin, pravastatin, and lovastatin.

Area of Science:

  • Pharmacology
  • Cardiovascular Medicine

Background:

  • Hydroxymethylglutaryl coenzyme A reductase inhibitors (statins) are widely prescribed for cholesterol management.
  • Rosuvastatin is a potent statin, but its precise dose equivalence to other statins is not well-established for substitution purposes.

Purpose of the Study:

  • To determine approximate equivalent doses of rosuvastatin compared to other statins.
  • To inform temporary substitution programs within lipid-lowering therapy.

Main Methods:

  • A comprehensive literature search was performed to identify direct comparative clinical trials.
  • Evaluated trials focused on the magnitude of cholesterol reduction between rosuvastatin and other statins.

Main Results:

  • Mean low-density lipoprotein (LDL) and total cholesterol values were analyzed from selected clinical trials.

Related Experiment Videos

  • Results demonstrated that rosuvastatin is not equivalent to other statins on a milligram-per-milligram basis.

    • Conclusions:

    • Rosuvastatin exhibits higher potency than other statins.
    • It is estimated to be at least 2 times as potent as atorvastatin and 4 times as potent as simvastatin.
    • Rosuvastatin is at least 8 times more potent than pravastatin and lovastatin.